AbbVie (ABBV) announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma. The study demonstrated an improvement in progression-free survival. Improvements were observed in complete response rates, duration of response, and time to next treatment among patients treated with epcoritamab. The study did not demonstrate a statistically significant improvement in overall survival. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate improvement in PFS in patients with R/R DLBCL who were treated with a CD3xCD20 T-cell engaging bispecific monotherapy. The global study enrolled 483 patients with R/R DLBCL with at least one prior line of therapy who were ineligible for high-dose chemotherapy and autologous stem cell transplant. The adverse events observed in this study appear consistent with known safety of epcoritamab. AbbVie and Genmab (GMAB) are working to assess the potential impact of various factors, including the COVID-19 pandemic and the increased availability of novel anti-lymphoma therapies during the study timeline. The data will be submitted for presentation at a future medical meeting, and AbbVie and Genmab will engage global regulatory authorities to determine next steps.
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
Current: 220.770
Low
218.00
Averages
253.26
High
289.00
Citi
Neutral
downgrade
$235 -> $230
2026-01-27
New
Reason
Citi
Price Target
$235 -> $230
AI Analysis
2026-01-27
New
downgrade
Neutral
Reason
Citi lowered the firm's price target on AbbVie to $230 from $235 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Berenberg
Buy
maintain
$270 -> $275
2026-01-20
Reason
Berenberg
Price Target
$270 -> $275
2026-01-20
maintain
Buy
Reason
Berenberg raised the firm's price target on AbbVie to $275 from $270 and keeps a Buy rating on the shares. The firm upped its forecasts for AbbVie's Skyrizi and Rinvoq citing an "exceptional" growth outlook.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV
Unlock Now
Wedbush
Outperform
upgrade
$80 -> $147
2026-01-09
Reason
Wedbush
Price Target
$80 -> $147
2026-01-09
upgrade
Outperform
Reason
Wedbush raised the firm's price target on Revolution Medicines (RVMD) to $147 from $80 and keeps an Outperform rating on the shares. The firm notes that several news outlets have reported that Revolution is in talks with multiple parties to be acquired, including AbbVie (ABBV) and most recently Merck (MRK) who reported a valuation of between $28B and $32B was being discussed, but a deal was maybe not imminent and could take a few weeks to be finalized. Given the evolving news cycle, Wedbush is assuming the Financial Times report on Merck is likely accurate.
Wolfe Research
Outperform -> Peer Perform
downgrade
2026-01-08
Reason
Wolfe Research
Price Target
2026-01-08
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded AbbVie to Peer Perform from Outperform.
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
